Zkusit zdarma
Beam Therapeutics Inc.

Beam Therapeutics Inc.

BEAM
Cena:
$ 28.64
+0.97 (3.51%)
Valuace
100
Růst
75
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

14:05 20-05-2026

Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its ...

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

16:00 18-05-2026

Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including...

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?

14:05 18-05-2026

Beam Therapeutics develops precision genetic medicines using base editing technology to target serio...

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

12:00 13-05-2026

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., ...

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

11:49 13-05-2026

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and p...

Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story

Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story

9:46 13-05-2026

Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine compa...

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

9:30 12-05-2026

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechn...

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

13:11 08-05-2026

Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates...

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

9:56 07-05-2026

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.91 per share versus the Zacks Con...

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

7:00 07-05-2026

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose...

Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM

Concurrent Investment Advisors LLC Invests $2.13 Million in Beam Therapeutics Inc. $BEAM

14:10 29-04-2026

Concurrent Investment Advisors LLC acquired a new stake in Beam Therapeutics Inc. (NASDAQ: BEAM) in ...

3 Biotech Stocks That Could Benefit from the Patent Cliff

3 Biotech Stocks That Could Benefit from the Patent Cliff

7:06 27-04-2026

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 al...

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

9:20 11-04-2026

CEO John Evans sold 30,078 company shares for a transaction value of ~$739,000 on April 1, 2026. The...

Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares

Beam Therapeutics (NASDAQ:BEAM) Insider Christine Bellon Sells 5,956 Shares

5:40 07-04-2026

Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Christine Bellon sold 5,956 shares o...

Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares

Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares

5:40 07-04-2026

Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Amy Simon sold 6,700 shares of the b...

Beam Therapeutics (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 11,810 Shares

Beam Therapeutics (NASDAQ:BEAM) President Giuseppe Ciaramella Sells 11,810 Shares

5:07 07-04-2026

Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) President Giuseppe Ciaramella sold 11,810 sh...

SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM

SG Americas Securities LLC Acquires 60,249 Shares of Beam Therapeutics Inc. $BEAM

5:32 04-04-2026

SG Americas Securities LLC lifted its stake in shares of Beam Therapeutics Inc. (NASDAQ: BEAM) by 13...

Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026

Beam Therapeutics’ BEAM-302 Hits Protective AAT Levels in AATD; 60 mg Picked for Pivotal in H2 2026

2:34 27-03-2026

Beam Therapeutics (NASDAQ: BEAM) executives and clinical collaborators presented updated top-line da...

BEAM Eyes Global Expansion of AATD Study After Strong Early Data

BEAM Eyes Global Expansion of AATD Study After Strong Early Data

12:10 26-03-2026

Beam Therapeutics reports promising phase I/II data for BEAM-302 in AATD, showing strong efficacy, t...

Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

22:15 25-03-2026

Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin ...

close

BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR ITS GENETIC DISEASE AND HEMATOLOGY FRANCHISES TO DRIVE EXECUTION OF LATE-STAGE CLINICAL PROGRAMS AND EXTENDS ITS OPERATING RUNWAY THROUGH COMMERCIAL TRANSITION

11-01-2026
ALIGNMENT REACHED WITH U.S. FDA ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR BEAM-302 IN ALPHA-1 AN...
Více zde

BEAM THERAPEUTICS TO PRESENT AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

18-12-2025
CAMBRIDGE, MASS., DEC. 18, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

BEAM THERAPEUTICS REPORTS UPDATED DATA FROM BEACON PHASE 1/2 TRIAL OF RISTOGLOGENE AUTOGETEMCEL (RISTO-CEL) HIGHLIGHTING DURABLE, DIFFERENTIATED PROFILE IN SICKLE CELL DISEASE (SCD) AT AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

06-12-2025
UPDATED DATA FROM 31 ADULT AND ADOLESCENT SCD PATIENTS  TREATED WITH RISTO-CEL (FORMERLY BEAM-101) ...
Více zde

BEAM THERAPEUTICS TO PARTICIPATE IN 2025 JEFFERIES LONDON HEALTHCARE CONFERENCE

12-11-2025
CAMBRIDGE, MASS., NOV. 12, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

BEAM THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS UPDATES

04-11-2025
EXPANDED DOSE EXPLORATION IN PART A AND DOSE ESCALATION IN PART B OF BEAM-302 PHASE 1/2 STUDY IN ALP...
Více zde

BEAM THERAPEUTICS TO PRESENT UPDATED DATA FROM BEACON PHASE 1/2 TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

03-11-2025
CAMBRIDGE, MASS., NOV. 03, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

JIM BEAM AND THE CADILLAC FORMULA 1® TEAM ANNOUNCE GLOBAL PARTNERSHIP, FUELING A VISION TO REACH NEW AUDIENCES

17-09-2025
TWO AMERICAN ORIGINALS UNITED ON ONE WORLD STAGE CLERMONT, KY. AND FISHERS, IND....
Více zde

BEAM THERAPEUTICS TO PARTICIPATE IN UPCOMING SEPTEMBER 2025 INVESTOR CONFERENCES

25-08-2025
CAMBRIDGE, MASS., AUG. 25, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

BEAM THERAPEUTICS ANNOUNCES U.S. FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO BEAM-101 FOR THE TREATMENT OF SICKLE CELL DISEASE

14-08-2025
CAMBRIDGE, MASS., AUG. 14, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

BEAM THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES UPDATE ON BEAM-302 DEVELOPMENT PROGRESS IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)

05-08-2025
WITH 17 PATIENTS DOSED IN THE PHASE 1/2 TRIAL, BEAM-302 CONTINUES TO DEMONSTRATE DURABLE CORRECTION ...
Více zde

BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 SUPPORTING DIFFERENTIATED PROFILE IN SICKLE CELL DISEASE (SCD) AT EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2025 CONGRESS

13-06-2025
UPDATED DATA FROM 17 PATIENTS CONSISTENT WITH PREVIOUSLY PRESENTED DATA; ALL PATIENTS TREATED WITH B...
Více zde

BEAM THERAPEUTICS ANNOUNCES U.S. FDA ORPHAN DRUG DESIGNATION GRANTED TO BEAM-101 FOR THE TREATMENT OF SICKLE CELL DISEASE

03-06-2025
CAMBRIDGE, MASS., JUNE 03, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

BEAM THERAPEUTICS ANNOUNCES U.S. FDA ORPHAN DRUG DESIGNATION GRANTED TO BEAM-302 FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)

29-05-2025
CAMBRIDGE, MASS., MAY 29, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECHN...
Více zde

BEAM THERAPEUTICS TO HIGHLIGHT NEW DATA FROM BEAM-101 PROGRAM IN SICKLE CELL DISEASE AT EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2025 CONGRESS

14-05-2025
PRESENTATION TO INCLUDE UPDATED DATA FROM 17 SICKLE CELL DISEASE PATIENTS IN THE ONGOING BEACON PHAS...
Více zde

BEAM THERAPEUTICS TO PARTICIPATE IN 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

13-05-2025
CAMBRIDGE, MASS., MAY 13, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECHN...
Více zde

BEAM THERAPEUTICS ANNOUNCES U.S. FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO BEAM-302 FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)

12-05-2025
CAMBRIDGE, MASS., MAY 12, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECHN...
Více zde

BEAM THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

06-05-2025
FIRST PATIENT DOSED IN THE PHASE 1/2 STUDY OF BEAM-301 IN GLYCOGEN STORAGE DISEASE TYPE IA, BEAM'S S...
Více zde

BEAM THERAPEUTICS PRESENTS ADDITIONAL DATA FOR BEAM-302 IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) AT 2025 ALPHA-1 FOUNDATION 7TH GLOBAL RESEARCH CONFERENCE AND 10TH PATIENT CONGRESS

05-04-2025
NEW DATA DEMONSTRATE PROPORTION OF CORRECTED M-AAT REACHED A MEAN OF 91% OF TOTAL AAT IN CIRCULATION...
Více zde

BEAM THERAPEUTICS ANNOUNCES CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR BEAM-302 FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) BY THE UNITED STATES (U.S.) FOOD AND DRUG ADMINISTRATION

27-03-2025
U.S. IND REPRESENTS REGULATORY CLEARANCE FOR BEAM-302 SPANNING SIX COUNTRIES AND SECOND OPEN IND FOR...
Více zde

BEAM THERAPEUTICS ANNOUNCES PRICING OF UNDERWRITTEN OFFERING

10-03-2025
CAMBRIDGE, MASS., MARCH 10, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTEC...
Více zde

BEAM THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA FOR BEAM-302 IN THE PHASE 1/2 TRIAL IN ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD), DEMONSTRATING FIRST EVER CLINICAL GENETIC CORRECTION OF A DISEASE-CAUSING MUTATION

10-03-2025
SINGLE DOSE OF BEAM-302 LED TO DURABLE, DOSE-DEPENDENT INCREASES IN TOTAL AND FUNCTIONAL ALPHA-1 ANT...
Více zde

BEAM THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2024 FINANCIAL RESULTS AND REITERATES ANTICIPATED CATALYSTS

25-02-2025
ENROLLMENT TARGET FOR ADULT SICKLE CELL DISEASE PATIENTS ACHIEVED IN BEACON TRIAL OF BEAM-101; DOSIN...
Více zde

BEAM THERAPEUTICS TO PARTICIPATE IN UPCOMING MARCH 2025 INVESTOR CONFERENCES

24-02-2025
CAMBRIDGE, MASS., FEB. 24, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

BEAM THERAPEUTICS TO PARTICIPATE IN GUGGENHEIM SMID CAP BIOTECH CONFERENCE

30-01-2025
CAMBRIDGE, MASS., JAN. 30, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

BEAM THERAPEUTICS TO ENCORE DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT 2025 TANDEM MEETINGS OF ASTCT AND CIBMTR

23-01-2025
CAMBRIDGE, MASS., JAN. 23, 2025 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

BEAM THERAPEUTICS ANNOUNCES PROGRESS IN HEMATOLOGY AND GENETIC DISEASE FRANCHISES AND OUTLINES KEY 2025 ANTICIPATED CATALYSTS

13-01-2025
MORE THAN 40 ADULT SICKLE CELL DISEASE PATIENTS NOW ENROLLED IN BEACON TRIAL OF BEAM-101; BEAM EXPEC...
Více zde

BEAM THERAPEUTICS PRESENTS NEW NON-HUMAN PRIMATE (NHP) DATA DEMONSTRATING PROOF-OF-CONCEPT FOR ESCAPE, A NON-GENOTOXIC, ANTIBODY-BASED CONDITIONING APPROACH TO TREATING SICKLE CELL DISEASE, AT AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

08-12-2024
NHP DATA SHOWED CD117 MONOCLONAL ANTIBODY (MAB) CONDITIONING SUCCESSFULLY ACHIEVED LONG-TERM ENGRAFT...
Více zde

BEAM THERAPEUTICS ANNOUNCES NEW DATA FROM BEACON PHASE 1/2 CLINICAL TRIAL OF BEAM-101 IN SICKLE CELL DISEASE AT AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

07-12-2024
ALL SEVEN PATIENTS TREATED WITH BEAM-101 ACHIEVED HEMOGLOBIN F (HBF) INDUCTION OF >60%, HEMOGLOBIN S...
Více zde

BEAM THERAPEUTICS ANNOUNCES APPOINTMENT OF SRAVAN EMANY AS CHIEF FINANCIAL OFFICER

06-12-2024
CAMBRIDGE, MASS., DEC. 06, 2024 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

BEAM THERAPEUTICS EXPANDS ITS BOARD OF DIRECTORS WITH APPOINTMENT OF CHIRFI GUINDO, GLOBAL BIOPHARMA STRATEGY AND COMMERCIAL LEADER

04-12-2024
CAMBRIDGE, MASS., DEC. 04, 2024 (GLOBE NEWSWIRE) -- BEAM THERAPEUTICS INC. (NASDAQ: BEAM), A BIOTECH...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-12 00:00:008-KStáhnout
2026-02-05 00:00:008-KStáhnout
2026-01-12 00:00:008-KStáhnout
2025-12-11 00:00:008-KStáhnout
2025-11-04 00:00:008-KStáhnout
2025-11-04 00:00:0010-QStáhnout
2025-08-05 01:00:008-KStáhnout
2025-08-05 01:00:0010-QStáhnout
2025-08-05 00:00:008-KStáhnout
2025-08-05 00:00:0010-QStáhnout
2025-07-03 01:00:008-KStáhnout
2025-07-03 00:00:008-KStáhnout
2025-06-06 01:00:008-KStáhnout
2025-06-06 00:00:008-KStáhnout
2025-05-06 01:00:008-KStáhnout
2025-05-06 01:00:0010-QStáhnout
2025-05-06 00:00:008-KStáhnout
2025-05-06 00:00:0010-QStáhnout
2025-03-10 00:00:008-KStáhnout
2025-03-09 23:00:008-KStáhnout
2025-02-25 00:00:008-KStáhnout
2025-02-25 00:00:0010-KStáhnout
2025-02-24 23:00:008-KStáhnout
2025-02-24 23:00:0010-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-12-09 00:00:008-KStáhnout
2024-12-08 23:00:008-KStáhnout
2024-12-06 00:00:008-KStáhnout
2024-12-05 23:00:008-KStáhnout
2024-12-04 00:00:008-KStáhnout
2024-12-03 23:00:008-KStáhnout
2024-11-05 00:00:008-KStáhnout
2024-11-05 00:00:0010-QStáhnout
2024-11-04 23:00:008-KStáhnout
2024-11-04 23:00:0010-QStáhnout
2024-08-06 01:00:008-KStáhnout
2024-08-06 01:00:0010-QStáhnout
2024-08-06 00:00:008-KStáhnout
2024-08-06 00:00:0010-QStáhnout
2024-07-15 01:00:008-KStáhnout
2024-07-15 00:00:008-KStáhnout
2024-06-10 01:00:008-KStáhnout
2024-06-10 00:00:008-KStáhnout
2024-02-27 00:00:008-KStáhnout
2024-02-27 00:00:0010-KStáhnout
2024-02-26 23:00:008-KStáhnout
2024-02-26 23:00:0010-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2023-12-14 00:00:008-KStáhnout
2023-12-13 23:00:008-KStáhnout
2023-11-08 00:00:008-KStáhnout
2023-11-08 00:00:0010-QStáhnout
2023-11-07 23:00:008-KStáhnout
2023-11-07 23:00:0010-QStáhnout
2023-10-31 00:00:008-KStáhnout
2023-10-30 23:00:008-KStáhnout
2023-10-19 01:00:008-KStáhnout
2023-10-19 00:00:008-KStáhnout
2023-08-08 01:00:008-KStáhnout
2023-08-08 01:00:0010-QStáhnout
2023-08-08 00:00:008-KStáhnout
2023-08-08 00:00:0010-QStáhnout
2023-06-08 01:00:008-KStáhnout
2023-06-08 00:00:008-KStáhnout
2023-05-10 01:00:008-KStáhnout
2023-05-10 01:00:0010-QStáhnout
2023-05-10 00:00:008-KStáhnout
2023-05-10 00:00:0010-QStáhnout
2023-02-28 00:00:008-KStáhnout
2023-02-28 00:00:0010-KStáhnout
2023-02-27 23:00:008-KStáhnout
2023-02-27 23:00:0010-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-11-07 00:00:008-KStáhnout
2022-11-07 00:00:0010-QStáhnout
2022-11-06 23:00:008-KStáhnout
2022-11-06 23:00:0010-QStáhnout
2022-09-07 01:00:008-KStáhnout
2022-09-07 00:00:008-KStáhnout
2022-08-30 01:00:008-KStáhnout
2022-08-30 00:00:008-KStáhnout
2022-08-09 01:00:008-KStáhnout
2022-08-09 01:00:0010-QStáhnout
2022-08-09 00:00:008-KStáhnout
2022-08-09 00:00:0010-QStáhnout
2022-08-01 01:00:008-KStáhnout
2022-08-01 00:00:008-KStáhnout
2022-06-10 01:00:008-KStáhnout
2022-06-10 00:00:008-KStáhnout
2022-05-09 01:00:008-KStáhnout
2022-05-09 01:00:0010-QStáhnout
2022-05-09 00:00:008-KStáhnout
2022-05-09 00:00:0010-QStáhnout
2022-02-28 00:00:008-KStáhnout
2022-02-28 00:00:0010-KStáhnout
2022-02-27 23:00:008-KStáhnout
2022-02-27 23:00:0010-KStáhnout
2022-01-10 00:00:008-KStáhnout
2022-01-09 23:00:008-KStáhnout
2021-11-08 00:00:008-KStáhnout
2021-11-08 00:00:0010-QStáhnout
2021-11-07 23:00:008-KStáhnout
2021-11-07 23:00:0010-QStáhnout
2021-08-10 01:00:008-KStáhnout
2021-08-10 01:00:0010-QStáhnout
2021-08-10 00:00:008-KStáhnout
2021-08-10 00:00:0010-QStáhnout
2021-07-07 01:00:008-KStáhnout
2021-07-07 00:00:008-KStáhnout
2021-06-11 01:00:008-KStáhnout
2021-06-11 00:00:008-KStáhnout
2021-05-24 01:00:008-KStáhnout
2021-05-24 00:00:008-KStáhnout
2021-05-11 01:00:008-KStáhnout
2021-05-11 01:00:0010-QStáhnout
2021-05-11 00:00:008-KStáhnout
2021-05-11 00:00:0010-QStáhnout
2021-04-23 01:00:008-KStáhnout
2021-04-23 00:00:008-KStáhnout
2021-04-01 01:00:008-KStáhnout
2021-04-01 00:00:008-KStáhnout
2021-03-15 00:00:008-KStáhnout
2021-03-15 00:00:0010-KStáhnout
2021-03-14 23:00:008-KStáhnout
2021-03-14 23:00:0010-KStáhnout
2021-02-23 00:00:008-KStáhnout
2021-02-22 23:00:008-KStáhnout
2021-01-19 00:00:008-KStáhnout
2021-01-18 23:00:008-KStáhnout
2021-01-13 00:00:008-KStáhnout
2021-01-12 23:00:008-KStáhnout
2021-01-12 00:00:008-KStáhnout
2021-01-11 23:00:008-KStáhnout
2021-01-11 00:00:008-KStáhnout
2021-01-10 23:00:008-KStáhnout
2020-11-10 00:00:008-KStáhnout
2020-11-10 00:00:0010-QStáhnout
2020-11-09 23:00:008-KStáhnout
2020-11-09 23:00:0010-QStáhnout
2020-08-12 01:00:008-KStáhnout
2020-08-12 01:00:0010-QStáhnout
2020-08-12 00:00:008-KStáhnout
2020-08-12 00:00:0010-QStáhnout
2020-06-29 01:00:008-KStáhnout
2020-06-29 00:00:008-KStáhnout
2020-05-12 01:00:008-KStáhnout
2020-05-12 01:00:0010-QStáhnout
2020-05-12 00:00:008-KStáhnout
2020-05-12 00:00:0010-QStáhnout
2020-03-30 01:00:008-KStáhnout
2020-03-30 01:00:0010-KStáhnout
2020-03-30 00:00:008-KStáhnout
2020-03-30 00:00:0010-KStáhnout
2020-02-11 00:00:008-KStáhnout
2020-02-10 23:00:008-KStáhnout
preloader